In a model of depression, zileuton significantly improved depressive‐like behavior by suppressing hippocampal TNF α, IL-1β, nuclear NF-κB p65 and microglial activation, reducing neuronal apoptosis and restoring synaptic proteins and neurogenesis (Liu et al., 2020). Here, IL1B is linked to depressive disorder.